Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations, comprises the Phase II MAvERIC-Pilot study and the Phase III MAVERIC trial. The ARCHER trial is a Phase II study in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.
Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding $30 billion annually.
Company Details
- Employees
- 27
- Founded
- -
- Address
- 2265 Upper Middle Rd E, Suite 602,canada
- Phone
- 289.910.0850
- in****@****lrx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- cardiolrx.com
- Keywords
- Heart Failure, Drug Delivery, Biotechnology, Myocarditis, Therapeutics, Heart Disease, Research, Clinical-stage, Formulation, Heart, Pericarditis.
- HQ
- Greater Toronto Area, Ontario
Cardiol Therapeutics Inc. Questions
Cardiol Therapeutics Inc.'s helpline number is 289.910.0850
Cardiol Therapeutics Inc.'s website is cardiolrx.com
Cardiol Therapeutics Inc.'s LinkedIn profile is https://ca.linkedin.com/company/cardiolrx
Cardiol Therapeutics Inc. has
27 employees.
View email and phone details for 27
employees at Cardiol Therapeutics Inc..
Cardiol Therapeutics Inc.'s industry is
Biotechnology Research
Cardiol Therapeutics Inc.'s top competitors are
Front Line Medical Technologies Inc.,
Edesa Biotech, Inc.,
Cipher Pharmaceuticals Inc. (Tsx: Cph) (Otcqx:cphrf),
Antibe Therapeutics Inc.,
Hls Therapeutics Inc.,
Ventyx Biosciences,
Virica Biotech,
Mint Pharmaceuticals,
Apotex Inc.,
Alectos Therapeutics Inc..
Cardiol Therapeutics Inc.'s support email address is info@cardiolrx.com
Cardiol Therapeutics Inc.'s categories are Biotechnology Research
Cardiol Therapeutics Inc.'s founding year is 2017
